[HTML][HTML] Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of Hepatitis B or Hepatitis C infection
M Megna, C Patruno, MR Bongiorno… - Clinical Drug …, 2022 - Springer
Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, M Bongiorno… - CLINICAL DRUG …, 2022 - iris.unipa.it
Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-alpha therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-alpha therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, MR Bongiorno… - CLINICAL DRUG …, 2022 - iris.unina.it
Background and objective: Biologics for psoriasis, especially anti-tumor necrosis factor-α
therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as …
therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as …
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, MR Bongiorno… - CLINICAL DRUG …, 2022 - iris.unisa.it
Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-alpha therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-alpha therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
[HTML][HTML] Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, MR Bongiorno… - Clinical Drug …, 2022 - ncbi.nlm.nih.gov
Methods This was a retrospective cohort study of patients with moderate-to-severe psoriasis
treated with secukinumab at seven Italian centers. Patients serologically positive for one or …
treated with secukinumab at seven Italian centers. Patients serologically positive for one or …
[引用][C] Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, MR Bongiorno… - CLINICAL DRUG …, 2022 - iris.unicz.it
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World
Setting of Hepatitis B or Hepatitis C Infection IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
Setting of Hepatitis B or Hepatitis C Infection IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
M Megna, C Patruno, MR Bongiorno… - Clinical Drug …, 2022 - europepmc.org
Methods This was a retrospective cohort study of patients with moderate-to-severe psoriasis
treated with secukinumab at seven Italian centers. Patients serologically positive for one or …
treated with secukinumab at seven Italian centers. Patients serologically positive for one or …
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real‑World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, MR Bongiorno… - Clinical Drug …, 2022 - search.proquest.com
Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-a therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-a therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
M Megna, C Patruno, MR Bongiorno… - Clinical drug …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and objective Biologics for psoriasis, especially anti-tumor necrosis factor-α
therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as …
therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as …
Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection.
M Megna, C Patruno, MR Bongiorno, A Gambardella… - 2022 - cabidigitallibrary.org
Abstract Background and Objective: Biologics for psoriasis, especially anti-tumor necrosis
factor-a therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-a therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …